Neos Therapeutics (NEOS) Reports Q2 Loss of $1.65/Share
- Donald Trump Sworn in as 45th U.S. President
- Wall St. trims gains as President Trump speaks
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Herbalife (HLF) Says SEC Requested Documents on Anti-Corruption Compliance in China; Reviewed with DoJ
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Neos Therapeutics (NASDAQ: NEOS) reported Q2 EPS of ($1.65), versus ($7.76) reported last year. Revenue for the quarter came in at $1.49 million, versus $1.48 million reported last year.
For earnings history and earnings-related data on Neos Therapeutics (NEOS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Herbalife (HLF) Provides Q4, FY17 Guidance in Memorandum for $1.325B Credit Facility; Lowers FY17 Sales Guidance
- Bassett Furniture (BSET) PT Raised to $28 at Stifel Following 4Q EPS Beat
- Regions Financial (RF) Reports In-Line Q4 EPS
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!